Company / Financials
Senti Biosciences Holdings, Inc. Financials
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$0
FY2025 · -100.0% YoY
Net Income
-$52.8M
FY2025 · +25.7% YoY
Profit Margin
-
FY2025 · net income / revenue
ROE
-205.8%
FY2025 · return on equity
Total Assets
$51.2M
FY2025
Total Debt
-
FY2025
Equity
$25.6M
FY2025
ROA
-103.1%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$0-100.0% YoYNet Income HistoryProfit after all expenses and taxes-$52.8M+25.7% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$61.0M+34.2% YoYSG&A Expense HistorySelling, general, and administrative expenses$26.4M-29.1% YoYR&D Expense HistoryResearch and development spending$34.4M+6.9% YoYIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$12.03+24.9% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$12.03+24.9% YoYShares Outstanding HistoryWeighted average diluted shares outstanding4.8M+5.7% YoYTotal Assets HistoryTotal value of all assets owned$51.2M-47.6% YoY